Table 1.

Clinical data of 34 patients with follicular lymphoma and pretreatment circulating t(14;18)-positive cells

n%
Sex   
 Male 21 62  
 Female 13 38 
Age   
 Median (y) 52  
 Range (y) 30-79  
Ann Arbor stage   
 Stage II bulky or III 11 32  
 Stage IV 23 68  
Systemic symptoms 21  
Bulky disease 17 52  
Bone marrow involvement* 23 72  
Leukemic 6  
Previous wait-and-see policy   
 n 21  
 Median period (mo) 20  
 Range (mo) 9-32 
Response to 8 CVP + IFN   
 Complete remission 16 44 
 Partial remission 11 34  
 Stable disease 
 Progressive disease 16  
End of protocol treatment   
 Insufficient response to induction 29  
 Toxicity of induction 13 
 Progression during maintenance 37  
 Toxicity of maintenance 21 
n%
Sex   
 Male 21 62  
 Female 13 38 
Age   
 Median (y) 52  
 Range (y) 30-79  
Ann Arbor stage   
 Stage II bulky or III 11 32  
 Stage IV 23 68  
Systemic symptoms 21  
Bulky disease 17 52  
Bone marrow involvement* 23 72  
Leukemic 6  
Previous wait-and-see policy   
 n 21  
 Median period (mo) 20  
 Range (mo) 9-32 
Response to 8 CVP + IFN   
 Complete remission 16 44 
 Partial remission 11 34  
 Stable disease 
 Progressive disease 16  
End of protocol treatment   
 Insufficient response to induction 29  
 Toxicity of induction 13 
 Progression during maintenance 37  
 Toxicity of maintenance 21 

CVP indicates cyclophosphamide, vincristine, and prednisone courses; IFN, interferon alpha-2b.

*

Bone marrow examination performed in 32 of 34 patients.

24 of 34 patients ended treatment according to the protocol; others continued treatment.

or Create an Account

Close Modal
Close Modal